BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23348804)

  • 1. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.
    Olszewski AJ; Castillo JJ
    Ann Oncol; 2013 May; 24(5):1352-9. PubMed ID: 23348804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
    Olszewski AJ; Ali S
    Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
    Olszewski AJ; Shafqat H; Ali S
    Leuk Lymphoma; 2015 Apr; 56(4):942-50. PubMed ID: 24956144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
    Pinnix CC; Gunther JR; Milgrom SA; Cruz Chamorro RJ; Medeiros LJ; Khoury JD; Amini B; Neelapu S; Lee HJ; Westin J; Fowler N; Nastoupil L; Dabaja B
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):447-455. PubMed ID: 30769175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
    Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
    J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
    Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
    Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
    Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
    Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
    Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
    Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.
    Portell CA; Aronow ME; Rybicki LA; Macklis R; Singh AD; Sweetenham JW
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):203-10. PubMed ID: 24417911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy in Early-stage Gastric MALT: Improved Survival Without Increased Cardiac Death.
    De Leo AN; Bates JE; Lockney NA; Mendenhall NP; Shaikh ME; Morris CG; Hoppe BS
    Am J Clin Oncol; 2020 Nov; 43(11):770-775. PubMed ID: 32841963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
    Olszewski AJ; Winer ES; Castillo JJ
    Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
    Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
    Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
    Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage I and II MALT lymphoma: results of treatment with radiotherapy.
    Tsang RW; Gospodarowicz MK; Pintilie M; Bezjak A; Wells W; Hodgson DC; Crump M
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1258-64. PubMed ID: 11483337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.